In 2021, the endoscope reprocessing industry was worth around USD 1,879.9 million, and it is projected to advance at a 9.8% CAGR from 2021 to 2030, hitting USD 4,358.1 million by 2030, according to P&S Intelligence.
 |
| To learn more about this report: https://bit.ly/3GotClz |
This growth can be credited to the increasing leaning toward minimally invasive methods, the spreading risk of numerous contaminations related with contaminated endoscopes, and the rising strict government guidelines spanning throughout the world to control such infections.
In 2021, the high-level disinfectants and test strips category, held the market share of around 35%, credited to the increasing occurrence of numerous endogenous infections, including bacteremia and pneumonia, after the usage of endoscopy measures.
North America held the largest revenue share of approximately 1.0 billion, in the endoscope reprocessing market. This can be ascribed to the increase in fondness for minimally invasive methods, outgrowth in cancer cases, and supportive repayment situations in the continent. For example, the Indian government amplified its healthcare spending to approximately 1.8% of its GDP in 2021– 2022, which was approximately 1.5% in 2020–2022.
Furthermore, the existence of massive manufacturers of medicinal devices, including Stryker Corporation, Boston Scientific Corporation, Cantel Medical Corp., and Conmed Corporation leads to the simple obtainability of not only endoscopes but also OEM repair facilities.
Hence, increasing leaning toward minimally invasive methods, the spreading risk of numerous contaminations related with contaminated endoscopes, and the rising strict government guidelines spanning throughout the world to control such infections, are the major factors propelling endoscope reprocessing market.
No comments:
Post a Comment